Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Idecabtagene Vicleucel in Relapsed/Refractory or High-Risk Multiple Myeloma
2023-505183-10-00Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 5
01
Overview
Phase 2, open-label trial of idecabtagene vicleucel in multiple myeloma (MM) (3 cohorts), sponsored by Celgene Corporation. Primary endpoints: Overall response rate (ORR) (Cohort 1) and Complete response (CR) rate (Cohort 1b, Cohort 2a, Cohort 2b, Cohort 2c, Cohort 3). Started Feb 2024; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505183-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505183-10-00.